Form 4: AbbVie Executive Timothy J. Richmond Reports Stock and Option Awards

EVP and Chief HR Officer of AbbVie, Timothy J. Richmond, reports the vesting of performance-based stock awards and the grant of stock options.

Summary

• Timothy J. Richmond, EVP and Chief HR Officer of AbbVie, filed a Form 4 detailing changes in beneficial ownership.
• On February 13, 2025, Richmond acquired shares of AbbVie common stock under performance share and restricted stock unit awards.
• These awards vested based on the attainment of performance goals certified by the Compensation Committee of AbbVie's Board of Directors.
• Richmond acquired 17,986 shares under a performance share award granted on February 17, 2022, based on earnings per share and relative total shareholder return.
• He also acquired 7,378 shares, 5,792 shares, and 6,998 shares under performance-vesting restricted stock unit awards granted on February 17, 2022, February 16, 2023, and February 15, 2024, respectively, based on a relative return on equity measure.
• Additionally, Richmond was granted an option to buy 22,916 shares of AbbVie common stock at an exercise price of $192.86, which becomes exercisable in annual increments starting February 13, 2026.
• Following these transactions, Richmond beneficially owns 51,991 shares of AbbVie common stock and options to purchase 22,916 shares.
• The shares will be issued to the reporting person on February 28, 2025.

Sentiment

Score: 7

Explanation: The document is generally positive, reflecting the achievement of performance goals and the alignment of executive interests with shareholders. The vesting of awards and grant of options are standard practices, but the achievement of performance targets is a positive signal.

Positives

• The vesting of performance-based awards suggests that AbbVie has achieved certain financial performance targets, as certified by the Compensation Committee.
• The grant of stock options aligns Richmond's interests with those of shareholders, incentivizing him to drive long-term value creation.
• Increased share ownership by a key executive can be seen as a positive sign of confidence in the company's future prospects.

Future Outlook

The document does not contain explicit forward-looking statements, but the vesting of performance-based awards suggests an expectation of continued strong performance.

Industry Context

Executive compensation disclosures are standard practice for publicly traded companies and provide transparency into how management is incentivized. Performance-based equity awards are a common tool used to align executive interests with shareholder value creation in the pharmaceutical industry.

Comparison to Industry Standards

• AbbVie's use of performance-based equity awards is consistent with industry standards for executive compensation.
• Companies like Johnson & Johnson, Pfizer, and Merck also utilize similar compensation structures to incentivize their executives.
• The specific metrics used (EPS and relative return on equity) are common performance indicators in the pharmaceutical sector.

Stakeholder Impact

• Shareholders may view the vesting of performance-based awards as a positive sign of the company's performance.
• Employees may be motivated by the company's achievement of performance goals.
• The executive benefits from the vesting of awards and the grant of options.

Next Steps

• The shares will be issued to the reporting person on February 28, 2025.
• The stock options become exercisable in annual increments starting February 13, 2026.

Key Dates